Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial

Abstract

ObjectiveTo evaluate whether treating patients with very early inflammatory polyarthritis (IP) with a 3-week course of intramuscular (IM) methylprednisolone acetate may postpone the need for disease-modifying antirheumatic drugs (DMARDs) and prevent IP from evolving into rheumatoid arthritis (RA).MethodsPatients with very early IP (4–10 weeks’ duration) were randomised to receive three injections of either 80 mg IM methylprednisolone acetate or placebo, given at weekly intervals. Assessments were monthly until 6 months after the first injection, and then concluded at 12 months. The primary outcome was the need to start DMARDs by the 6-month assessment. Secondary outcomes included disease activity and final clinical diagnosis by the rheumatologist at 12 months.ResultsPatients in the placebo group (76%) were more likely to need DMARDs during the first 6 months of the trial than patients in the glucocorticoid group (61%) (adjusted OR = 2.11, 95% CI 1.16 to 3.85, p = 0.015). Disease activity did not differ between the two groups at 12 months, probably because many patients in the placebo group started DMARDs early in the study. After 12 months, the arthritis had resolved without the need for DMARDs in 9.9% (11/111) of the patients in the placebo group and in 19.8% (22/111) in the glucocorticoid-treated group (adjusted OR = 0.42, 95% CI 0.18 to 0.99, p = 0.048).ConclusionTreatment of patients with very early IP with IM methylprednisolone acetate appears to postpone the prescription of DMARDs and prevent one in 10 patients from progressing into RA.

Cost‐Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis

“…True positive patients had a 0.1 improvement in utility in the first year after diagnosis, with a baseline level of 0.6, based on REACH data and the literature (27)(28)(29)(30)(31). For the other patients, the literature is less clear.…”

Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis

“…Methotrexate can significantly delay the onset of RA development and radiographic progression, while the effect of abatacept is less striking in retarding progression to RA. Unfortunately, neither methylprednisolone [60,61] nor the biological DMARD infliximab (an anti-TNF agent) [62] in UA could prevent progression to RA. The other interesting intervention is immune tolerization with peptide antigens [63], but its benefit is still unclear.…”

New Recommendations for the Management of Rheumatoid Arthritis (Eular, 2013): The Role of Methotrexate

“…Примечательно, что раннее назначение других про-тивовоспалительных препаратов (короткий курс в виде мо-нотерапии), таких как ГК [27][28][29] и ИНФ [30], не предот-вращало прогрессирование НДА в РА, а эффект АБЦ [31] сходен с таковым у МТ (исследование ADJUST).…”